Incidence and Risk of Severe Neutropenia in Advanced Cancer Patients Treated with Cetuximab: A Meta-Analysis

Background and Aim: Neutropenia is a serious adverse event for patients who are treated with cetuximab, an inhibitor of endothelial growth factor receptor. However, there is no consistent result of the relationship between cetuximab and neutropenia in randomized controlled trials (RCTs). We did a sy...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Long, Chen, Yi-zhi, Shi, Duo, Shi, Xue-yin, Zou, Zui, Zhao, Jian-hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2012
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3586098/
https://www.ncbi.nlm.nih.gov/pubmed/22133387
http://dx.doi.org/10.2165/11598190-000000000-00000

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3586098/
https://www.ncbi.nlm.nih.gov/pubmed/22133387
http://dx.doi.org/10.2165/11598190-000000000-00000

Ejemplares similares